India's economic engine is revving up, but navigating the global headwinds requires sharp strategy. The rupee's recent volatility against the dollar underscores the complexities facing Indian businesses, impacting everything from import-export trade to domestic inflation. This week alone, we've seen significant shifts in the IT sector, with major players announcing restructuring and a renewed focus on AI-driven solutions. Meanwhile, the burgeoning startup ecosystem continues to attract substantial funding, despite a cautious global investor sentiment. The government's recent policy announcements on infrastructure development and digitalization are poised to further shape the business landscape, creating both opportunities and challenges for entrepreneurs and established corporations alike. Understanding these market dynamics is crucial for success in today's rapidly evolving Indian economy. Stay informed with Abtak.com for the latest insights and analysis on key sectors including finance, manufacturing, and technology – empowering your business decisions in a dynamic market. Explore the complete business news section now to stay ahead of the curve.
First & only immuno-oncology drug approved by various regulatory authorities around the world Dr. Reddy's Laboratories has announced the launch of Toripalimab in India. Toripalimab is a New Biological Entity (NBE). It is the only immuno-oncology drug approved by various regulatory authorities around the world such as United States Food and Drug Administration (USFDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). In 2023, Dr. Reddy's entered into a license and commercialisation agreement with Shanghai Junshi Biosciences for Toripalimab. Under this agreement, Dr. Reddy's obtained exclusive rights to develop and commercialise Toripalimab in 21 countries including India, South Africa, Brazil and various countries in Latin America. Additionally, the agreement allows Dr. Reddy's to expand the scope of the license to cover Australia, New Zealand and nine other countries. With this launch by Dr. Reddy's, India becomes the third country in the world after China and United States to receive access to this next generation PD-1 inhibitor. Dr. Reddy's will market it under the brand name Zytorvi® in India. The standard of care for RM-NPC in India before Toripalimab was chemotherapy (gemcitabine and cisplatin). Toripalimab is indicated as first-line treatment of adults with metastatic or recurrent locally advanced NPC in combination with gemcitabine and cisplatin. This combination has shown a 48% reduction in risk of progression or death. Additionally, Toripalimab has also been approved as monotherapy for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after platinum-containing chemotherapy. Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system's ability to attack and kill tumour cells. NPC is a malignant tumour that arises from the epithelium of the nasopharynx. According to GLOBOCAN 2022 statistics, the number of newly diagnosed NPC cases in 2022 exceeded 120,000 worldwide. In India, there were 6,519 newly diagnosed cases of NPC in 2022. The highest age-adjusted rates for NPC were found in the north-eastern states in India, with Kohima in Nagaland having an incidence of 19.4/100,000 population.
Mumbai: Dr Reddy's Laboratories has entered into a collaboration with Reykjavik, Ireland-based biotech company Alvotech to co-develop, manufacture and commercialise a biosimilar version of blockbuster cancer drug Keytruda for the global markets. Keytruda (generic name is pembrolizumab), manufactured and marketed by Merck & Co, is the most successful medicine, recording worldwide sales of $29.5 billion in 2024. It is used to treat multiple forms of cancer. Under the terms of the agreement, both companies will be jointly responsible for developing and manufacturing the biosimilar candidate and ...Read More >
Hyderabad: CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, on Monday said it has reported positive top-line Phase 3 results for BP11, its investigational biosimilar to Xolair, or omalizumab.CuraTeQ said the study met all primary endpoints in patients with chronic spontaneous urticaria receiving the 300 mg dose, demonstrating high comparability with the reference product. The company said it plans to use the results to support regulatory submissions for chronic spontaneous urtica ...Read More >
Indian markets saw gains on Friday. Britannia Industries is focusing on localized strategies. Hyundai aims for growth through domestic sales and exports. Alembic Pharma received US FDA EIR. Diamond Power secured a Rs 236 crore order from Adani Energy. GMR Airports reported a passenger traffic decline. RailTel received a Rs 209 crore order. Markets extended their winning streak on Friday, gaining nearly half a percent, in line with favorable global and domestic cues. In today's trade, shares of G ...Read More >
(RTTNews) - Indian shares were moving lower on Monday amid concerns over persistent selling by FIIs and renewed uncertainty around U.S.-India trade negotiations. Global sentiment also remains fragile as investors continue to reduce exposure to tech stocks on valuation concerns. The benchmark BSE Sensex was down 320 points, or 0.4 percent, at 84,946 in early trade, while the broader NSE Nifty index dipped 105 points, or 0.4 percent, to 25,941. Among the prominent decliners, TMPV, Power Grid Corp, Bajaj FinServ and Mahindra & Mahindra fell 1-2 percent. Dr Reddy's Laboratories fell about 1 pe ...Read More >
Childhood cancer is a disease no child should ever have to face. Yet, the reality is sobering: around four lakh children worldwide are diagnosed with cancer every year, and nearly 20% of these cases come from India. Awareness is the first step to changing outcomes. This is the most common and often the hardest question to answer. Unlike adult cancers, there are no proven lifestyle or environmental factors that cause cancer in children. Nearly 90% of childhood cancers are sporadic, meaning they h ...Read More >
New Delhi, Aug 12 (PTI) Drug firm Lupin on Tuesday said it has partnered with Switzerland-based Sandoz Group AG to commercialise its biosimilar ranibizumab across multiple regions. Under the terms of the agreement, Sandoz will oversee commercialisation of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia, the Mumbai-based drug maker said in a statement. Lupin will be responsible for manufacturing the product and for regulatory submissions, it added. As per the deal, Sandoz will hold exclusive marketing rights in most ...Read More >
Ahmedabad -- Senores Pharmaceuticals Limited today announced that it has entered into a definitive agreement to acquire 100% equity stake in Apnar Pharma Private Limited ("Apnar Pharma"), along with the acquisition of five Abbreviated New Drug Applications (ANDAs), marking a significant milestone in Senores' growth strategy across regulated pharmaceutical markets. Apnar Pharma, incorporated on December 12, 2014, is a privately held pharmaceutical company engaged in the licensing, development, and manufacturing of generic formulations for regulated markets including the United States, the Unit ...Read More >
, /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company received marketing authorization in from National Medical (TASE:PMCN) Products Administration (NMPA) for the first domestically developed trophoblast cell-surface antigen 2 (TROP2)-directed antibody"drug conjugate (ADC) sacituzumab tirumotecan (sac-™T, formerly SKB264/MK-2870) for adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one of them for advanced or metastatic s ...Read More >
Lords Mark Industries Ltd. secures US FDA Registration, Reinforces India's Position in Global Healthcare Manufacturing . 4 min read Last Updated : Oct 13 2025 | 1:16 PM IST Mumbai, October 11, 2025: Lords Mark Industries Ltd., has received US FDA registration for its range of surgical consumables, orthopedic supports, and hygiene products -- a milestone that reinforces its manufacturing excellence and strengthens India's position in the global healthcare supply chain. US FDA registration repr ...Read More >
Mumbai, Oct 31 (SocialNews.XYZ) Actress Deepika Padukone, who has been a strong advocate for mental health awareness, reacted to cricketer Jemimah Rodrigues' recent revelation about battling anxiety. The 'Om Shanti Om' actress, known for openly sharing her own struggles with depression in the past, praised Jemimah for her honesty and courage in speaking up, highlighting the importance of conversations around mental well-being in sports and beyond. Taking to her Instagram Stories, Deepika Padukone reshared a video of cricketer Jemimah Rodrigues, in which the athlete opened up about her struggl ...Read More >
Dr Reddy's Laboratories has received a report from the US Food and Drug Administration. The report concerns its manufacturing facility in Srikakulam, Andhra Pradesh. The USFDA has classified the inspection outcome as Voluntary Action Indicated. This means the inspection is officially closed. The company received the Establishment Inspection Report on October 20, 2025. Drugmaker Dr Reddy's Laboratories Ltd on Tuesday said it has received establishment inspection report from the US health regulato ...Read More >
Hyderabad, April 6 (RAHNUMA): CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has announced positive top-line results from its Phase 3 trial of BP11, an investigational biosimilar to Omalizumab (marketed as Xolair). The study met all primary endpoints, demonstrating strong comparability with the reference drug in treating chronic spontaneous urticaria (CSU) at a 300 mg dose. Conducted across 608 patients at nearly 80 sites in Europe and India, the trial showed precise equivalence in itch severity reduction at Week 12, aligning with requirements of both the Food and Drug Administration an ...Read More >
New Delhi, September 15: Dalal Street is expected to see selective stock action on Monday, September 15, as several companies announced key updates over the weekend. Market sentiment may remain stock-specific, with developments spanning acquisitions, order wins, regulatory observations, and fundraising plans. Investors are likely to track healthcare, infrastructure, and power sector plays closely, alongside midcaps riding on new contracts. Global cues and domestic macro trends will set the broader tone, but these individual stocks could see heightened activity based on fresh news flow. Trader ...Read More >
New Delhi, Jul 20 (PTI) Trading sentiment in the stock market this week will be guided by quarterly earning announcements from blue-chips such as Infosys and Bajaj Finance, the outcome of India-US trade talks and global cues, analysts said. Markets may on Monday react to the quarterly results of three heavyweights - Reliance Industries, HDFC Bank and ICICI Bank, an expert said. India's most valuable company Reliance Industries on Friday reported its highest-ever quarterly profit of Rs 26,994 crore for the June quarter, reflecting a growth of 78.3 per cent over the year-ago period, driven by ...Read More >